Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Receivables (2022 - 2025)

Amylyx Pharmaceuticals (AMLX) has 4 years of Receivables data on record, last reported at $188000.0 in Q4 2025.

  • For Q4 2025, Receivables fell 65.63% year-over-year to $188000.0; the TTM value through Dec 2025 reached $188000.0, down 65.63%, while the annual FY2025 figure was $188000.0, 65.63% down from the prior year.
  • Receivables reached $188000.0 in Q4 2025 per AMLX's latest filing, down from $232000.0 in the prior quarter.
  • Across five years, Receivables topped out at $40.6 million in Q4 2023 and bottomed at $137000.0 in Q3 2022.
  • Average Receivables over 4 years is $11.9 million, with a median of $3.0 million recorded in 2024.
  • Peak YoY movement for Receivables: skyrocketed 21398.54% in 2023, then crashed 98.65% in 2024.
  • A 4-year view of Receivables shows it stood at $15.8 million in 2022, then soared by 156.55% to $40.6 million in 2023, then plummeted by 98.65% to $547000.0 in 2024, then plummeted by 65.63% to $188000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $188000.0 in Q4 2025, $232000.0 in Q3 2025, and $203000.0 in Q2 2025.